Skip to main content
. 2022 Feb 15;24(1):12–19. doi: 10.1007/s11926-022-01055-9

Fig. 1.

Fig. 1

Proportion of patients receiving pegloticase and concomitant immunomodulatory therapy by year (2015–2019) [45•]. aPatients who started either methotrexate or azathioprine within 60 days of their first pegloticase infusion